Summit Therapeutics Inc. (SMMT) Free cash flow 2017–2025
Summit Therapeutics Inc. (SMMT) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$323.6MFY2025 · since FY2017: -$22.2M → -$323.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$323.6M | -127.5% |
| FY2024 | -$142.2M | -85.0% |
| FY2023 | -$76.9M | -82.2% |
| FY2022 | -$42.2M | +42.1% |
| FY2021 | -$72.9M | -50.2% |
| FY2020 | -$48.5M | — |
| FY2018 | -$35.3M | -59.1% |
| FY2017 | -$22.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SMMT financial trends
SMMT RevenueSMMT Net incomeSMMT Net marginSMMT Gross profitSMMT Gross marginSMMT Operating incomeSMMT Operating marginSMMT Operating cash flowSMMT Capital expendituresSMMT Return on equitySMMT Stock buybacksSMMT Dividends paidSMMT Total assetsSMMT Total liabilitiesSMMT Shareholders’ equitySMMT overview →